Last reviewed · How we verify
FLAVONE
At a glance
| Generic name | FLAVONE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Gastrointestinal intolerance
- Allergic reactions
- Idiosyncratic reactions
Key clinical trials
- Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression (PHASE2)
- Supplement Combination on Stress and Sleep (NA)
- A Phase III Clinical Trial Evaluating the Efficacy and Safety of TriThien Duoc Capsules in Grade II Internal Haemorrhoids Patients With Bleeding Compared to Diosmin. (PHASE3)
- Luteolin for the Treatment of People With Schizophrenia (NA)
- Silymarin vs Hesperidin/Diosmin in Fibromyalgia (NA)
- The Role of Luteolin Supplementation in Cellular Metabolism of Myocytes and Fat Cells, Physical Performance, and Body Composition in Athletes. (NA)
- Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis (NA)
- Using Flavonoids to Kill Hepatitis B Virus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLAVONE CI brief — competitive landscape report
- FLAVONE updates RSS · CI watch RSS